CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 6, 2004, Pages 516-528

  Katz, David A ^a,b   Grimm, David R ^a   Cassar, Steven C ^a   Gentile, Maria C ^a   Ye, Xin ^a   Rieser, Matthew J ^a   Gordon, Eric F ^a   Polzin, Jill E ^a   Gustavson, Linda E ^a   Driscoll, Rita M ^a   O'Dea, Robert F ^a   Williams, Laura A ^a   Bukofzer, Stanley ^a  

^a ABBOTT LABORATORIES   (United States)

^b R424/AP52 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETHROMYCIN; CYTOCHROME P450 3A; CYTOCHROME P450 3A5; GLYCOPROTEIN P; KETOLIDE; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; ENZYME SUBSTRATE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GEOMETRY; HEMOCONCENTRATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TIME;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ERYTHROMYCIN; FEMALE; GENES, MDR; GENOTYPE; HUMANS; KETOLIDES; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 2942567928     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.01.013     Document Type: Article

References (19)

1. Cholerton S., Daly A., Idle J. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci. 13:1992;434-439
2. Flockhart D. Cytochrome P450 drug interaction table. Available from: URL: http://medicine.iupui.edu/flockhart/
3. Thummel K., Shen D., Podoll T., Kunze K., Trager W., Bacchi C., et al. Use of midazolam as a human cytochrome P450 3A probe. II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther. 271:1994;557-566
4. Finta C., Zaphiropoulos P. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene. 260:2000;13-23
5. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 27:2001;383-391
6. Koch I., Weil R., Wolbold R., Brockmöller J., Hustert E., Burk O., et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos. 30:2002;1108-1114
7. Lin Y., Dowling A., Quigley S., Farin F., Zhang J., Lamba J., et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol. 62:2002;162-172
8. O'Brien R. A general ANOVA method for robust tests of additive models for variances. J Am Stat Assoc. 74:1979;877-880
9. Floyd M., Gervasini G., Masica A., Mayo G., George A., Bhat K., et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics. 13:2003;595-606
10. Shih P.-S., Huang J.-D. Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos. 30:2002;1491-1496
11. Kroetz D., Pauli-Magnus C., Hodges L., Huang C., Kawamoto M., Johns S., et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 13:2003;481-494
12. Goh B.-C., Lee S.-C., Wang L.-Z., Fan L., Guo J.-Y., Lamba J., et al. Explaining interindividual variability of docetaxel pharmacokinetics an pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 20:2002;3683-3690
13. Xie R., Knuth D., Tan L., Polasek E., Hong C., Teillol-Foo M., et al. Fexofenadine and midazolam disposition in relation to genetic polymorphisms of CYP3A, PXR and P-glycoprotein. [abstract] Clin Pharmacol Ther. 73:2003;P19
14. Macphee I., Fredericks S., Tai T., Syrris P., Carter N., Johnston A., et al. Tacrolimus pharmacogenetics polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation. 74:2002;1486-1489
15. Zheng H., Webber S., Zeevi A., Schuetz E., Zhang J., Bowman P., et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant. 3:2003;477-483
16. Hesselink D., van Schaik R., van der Heiden I., van der Werf M., Gregoor P.J., Lindemans J., et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 74:2003;245-254
17. Kim J., Chung J., Cho J., Lim H., Hong K., Oh D., et al. Identification of the influence of CYP3A5 genetic polymorphism in tacrolimus pharmacokinetics assessed from routine TDM data using population pharmacokinetics approach. [abstract] Clin Pharmacol Ther. 73:2003;P20
18. Yates C., Zhang W., Song P., Li S., Gaber A., Kotb M., et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 43:2003;555-564
19. Chung J., Cho J., Lim H., Hong K., Oh D., Yi S., et al. Contribution of CYP3A5 genetic polymorphism in cyclosporine pharmacokinetics assessed from routine TDM data using mixed effect modeling. [abstract] Clin Pharmacol Ther. 73:2003;P56